Cullin-3 mutation causes arterial stiffness and hypertension through a vascular smooth muscle mechanism

JCI Insight

Volumn 1, Issue 19, 2016, Pages

  Agbor, Larry N ^a   Ibeawuchi, Stella Rita C ^a   Hu, Chunyan ^a   Wu, Jing ^a   Davis, Deborah R ^a   Keen, Henry L ^a   Quelle, Frederick W ^a   Sigmund, Curt D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055601721     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.91015     Document Type: Article

References (30)

1. Pelham CJ, et al. Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab. 2012;16(4):462–472.
2. Boyden LM, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012;482(7383):98–102.
3. Furukawa M, He YJ, Borchers C, Xiong Y. Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat Cell Biol. 2003;5(11):1001–1007.
4. Ibeawuchi SR, Agbor LN, Quelle FW, Sigmund CD. Hypertension-causing mutations in Cullin3 protein impair RhoA protein ubiquitination and augment the association with substrate adaptors. J Biol Chem. 2015;290(31):19208–19217.
5. McCormick JA, et al. Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3. J Clin Invest. 2014;124(11):4723–4736.
6. Schumacher FR, et al. Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia. EMBO Mol Med. 2015;7(10):1285–1306.
7. Wakabayashi M, et al. Impaired KLHL3-mediated ubiquitination of WNK4 causes human hypertension. Cell Rep. 2013;3(3):858–868.
8. Louis-Dit-Picard H, et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet. 2012;44(4):456–60, S1–3.
9. Wilson FH, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293(5532):1107–1112.
10. Halabi CM, et al. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008;7(3):215–226.
11. De Silva TM, et al. Role of peroxisome proliferator-activated receptor-γ in vascular muscle in the cerebral circulation. Hypertension. 2014;64(5):1088–1093.
12. Beltran A, et al. Arterial compliance abnormalities in isolated systolic hypertension. Am J Hypertens. 2001;14(10):1007–1011.
13. Singer JD, Gurian-West M, Clurman B, Roberts JM. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev. 1999;13(18):2375–2387.
14. Ohh M, et al. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 2002;3(2):177–182.
15. Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ Res. 2016;118(2):352–366.
16. Kitazawa T, Gaylinn BD, Denney GH, Somlyo AP. G-protein-mediated Ca2+ sensitization of smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1991;266(3):1708–1715.
17. Sakurada S, et al. Ca2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res. 2003;93(6):548–556.
18. Chen Y, et al. Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. Mol Cell. 2009;35(6):841–855.
19. Leck YC, Choo YY, Tan CY, Smith PG, Hagen T. Biochemical and cellular effects of inhibiting Nedd8 conjugation. Biochem Biophys Res Commun. 2010;398(3):588–593.
20. Laurent S, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236–1241.
21. Kaess BM, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308(9):875–881.
22. Chen D, Coffman TM. The kidney and hypertension: lessons from mouse models. Can J Cardiol. 2012;28(3):305–310.
23. Damkjaer M, et al. Selective renal vasoconstriction, exaggerated natriuresis and excretion rates of exosomic proteins in essential hypertension. Acta Physiol (Oxf). 2014;212(1):106–118.
24. McCurley A, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18(9):1429–1433.
25. Evans LC, et al. Conditional Deletion of Hsd11b2 in the Brain Causes Salt Appetite and Hypertension. Circulation. 2016;133(14):1360–1370.
26. Stump M, et al. Effect of selective expression of dominant-negative PPARγ in pro-opiomelanocortin neurons on the control of energy balance. Physiol Genomics. 2016;48(7):491–501.
27. Hu C, Lu KT, Mukohda M, Davis DR, Faraci FM, Sigmund CD. Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction. Physiol Genomics. 2016;48(2):124–134.
28. Hartley CJ, Taffet GE, Reddy AK, Entman ML, Michael LH. Noninvasive cardiovascular phenotyping in mice. ILAR J. 2002;43(3):147–158.
29. Wu J, et al. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res. 2014;114(4):616–625.
30. Stump M, et al. Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development. Endocrinology. 2016;157(11):4266–4275.